Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response Dependent Treatment of Hodgkin's Disease (POG 9426)
NCT00002827Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 1996
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of dexrazoxane in Cardiotoxicity, pulmonary toxicity, sponsored by Children's Oncology Group. Started Oct 1996; status: completed.
02
Drugs
dexrazoxane
03
Conditions
Cardiotoxicitypulmonary toxicity
Beyond the preview
Go deeper on NCT00002827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002827.